H.C. Thomas was a medical student, Vanderbilt University School of Medicine, Nashville, Tennessee at the time of writing, and is currently a plastic surgery resident, MedStar Georgetown University Hospital, Washington, DC
Auto-generated profile, based on publicly available information
Harrison C. Thomas
H.C. Thomas was a medical student, Vanderbilt University School of Medicine, Nashville, Tennessee at the time of writing, and is currently a plastic surgery resident, MedStar Georgetown University Hospital, Washington, DC
Human milk oligosaccharides (HMOs) possess antimicrobial activity against a number of bacterial pathogens. HMOs prevent infection by serving as decoy receptors that competitively bind pathogens thus preventing pathogen attachment to host epithelial cell receptors. In a second mechanistic pathway, we recently demonstrated that heterogenous HMO extracts exert antimicrobial action against Group B Streptococcus by increasing cellular permeability. As human milk contains ca. 200 unique glycans however, our understanding of which pharmacophores are most important to HMO antimicrobial activity remains immature. In the present study, we describe the first evaluation of the antimicrobial and antibiofilm activities of five structurally defined, ubiquitous sialylated HMOs against Group B Streptococcus.
Group B Streptococcus is an important human pathogen that causes serious infections during pregnancy which can lead to chorioamnionitis, funisitis, premature rupture of gestational membranes, preterm birth, neonatal sepsis, and death. GBS is evolving antimicrobial resistance mechanisms, and the work presented in this paper provides evidence that prebiotics such as human milk oligosaccharides can act as adjuvants to restore the utility of antibiotics.